MedTrace Logo

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

NCT03758365 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-01-09

Study results available
· View outcomes & findings →

Summary

The objective of this trial is to compare the vasoconstriction potential

Conditions

  • Vasoconstriction

Interventions

DRUG

MC2-01 Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Clobetasol Propionate 0.05% Lotion

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Betamethasone Dipropionate 0.05% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Triamcinolone Acetonide 0.1% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Hydrocortisone Butyrate 0.1% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Desonide 0.05% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Vehicle

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Sponsors & Collaborators

  • MC2 Therapeutics

    lead INDUSTRY

Principal Investigators

  • Catherine QUEILLE-ROUSSEL, MD · CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-05
Primary Completion
2018-11-23
Completion
2018-11-23
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758365 on ClinicalTrials.gov